3093 Management of active multiple sclerosis after fingolimod cessation in the context of cryptococcal meningitis

BackgroundThere are at least 15 case reports published about cryptococcal meningitis (CM) in multiple sclerosis (MS) patients treated with fingolimod. The risk of CM associated with the use of fingolimod appears to increase with more than two years of therapy, lymphopenia, low CD4 counts and older a...

Full description

Saved in:
Bibliographic Details
Published in:BMJ neurology open 2024-08, Vol.6 (Suppl 1), p.A31-A32
Main Authors: Tran, Lucinda, Davies, Leo, Beadnall, Heidi
Format: Article
Language:English
Subjects:
Meningitis
Multiple sclerosis
Poster Abstracts
Steroids
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThere are at least 15 case reports published about cryptococcal meningitis (CM) in multiple sclerosis (MS) patients treated with fingolimod. The risk of CM associated with the use of fingolimod appears to increase with more than two years of therapy, lymphopenia, low CD4 counts and older age.1 It is generally recommended to avoid corticosteroid use during the induction phase of CM treatment due to associations with adverse outcomes.2 However, fingolimod cessation can be associated with rebound activity of MS.1 MethodsWe describe a case of a 35 year old female diagnosed with CM after 12 years of treatment with fingolimod for relapsing-remitting MS.ResultsIn this case corticosteroids were used to manage MS disease activity after induction treatment for CM with amphotericin B and flucytosine for two weeks. One week after stopping induction treatment, she developed severe headaches and repeat cerebrospinal fluid examination confirmed recurrent CM. She was given a further four weeks of induction treatment before corticosteroids were used again, due to the development of new active MS lesions on imaging.ConclusionThis case demonstrates the difficulties of rationalising corticosteroid use in a patient with MS and CM the context of fingolimod cessation.References Cuascut F, Alkabie S, Hutton GJ. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Mult Scler Relat Disord 2021;53:103072. doi:10.1016/j.msard.2021.103072. Liu J, Liu J, Yang L, et al. Review: the application of corticosteroids in cryptococcal meningitis. J Mycol Med 2023;33(2):101364. doi:10.1016/j.mycmed.2023.101364.
ISSN:2632-6140
DOI:10.1136/bmjno-2024-ANZAN.87